|
BioScreening - organic compounds for screening
Drug-Like Compounds NewsAlzheimer’s Research Provides Potential Treatment for UTI - One element links the disparate areas of research: amyloids, which are fibrous, sticky protein aggregates. Some infectious bacteria use amyloids to attach to host cells and to build biofilms, which are bacterial communities bound together in a film that helps resist antibiotics and immune attacks.
Amyloids also form in the nervous system in Alzheimer’s disease, Parkinson’s [...]
Families of Spinal Muscular Atrophy Funded Program Shows Quinazoline Compounds Give Survival Benefit in a Severe Mouse Model of SMA. - This publication, showing data from the testing of Quinazoline derivatives in a Spinal Muscular Atrophy mouse model, has been published in Human Molecular Genetics by lead author Dr. Matthew Butchbach from the laboratory of Dr. Arthur Burghes at the Ohio State University.
The generation of the Quinazoline compounds as a therapeutic drug candidate for Spinal Muscular Atrophy [...]
Tapeworm Drug May Hold Promise For Colon Cancer, Future Research - The findings about this compound, published in the Nov. 3 issue of Biochemistry journal, might prove valuable to patients and clinicians, who may benefit if there is a demonstrated boost to chemotherapy. Researchers also can use the compound to manipulate the receptor to learn more about a common cell replenishing pathway, called the Wnt pathway, [...]
Zelinsky Institute Inc. announced collaboration with ART-CHEM - Zelinsky Institute Inc. (Newark, DE, August 2009) - Zelinsky Institute Inc. expands its partnership and supplier network with the announcement of collaboration with one of the premier fine chemistry companies - ART-CHEM, which originated from Moscow, Russia, and has started its operations in Berlin, Germany, in 2005. ART-CHEM specializes in synthesis of highly diverse [...]
Sirona Biochem Says SGLT Test Results Confirm Key ‘Breakthrough’ - Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on diabetes and obesity, says results of testing its unique SGLT inhibitor molecules demonstrate a key breakthrough milestone for Sirona Biochem.
Sirona Biochem CEO, Dr. Howard Verrico, said, “There are two vital steps in the early stage of drug testing: validation of concept i.e. a molecule [...]
Agilux Laboratories Hires New Associate Director to Lead In Vitro ADMET Services Division - - Adrian Sheldon, Ph.D., Positions Contract Research Organization for Growth -
WORCESTER, Mass.--(Business Wire)--
Agilux Laboratories, Inc., a Contract Research Organization (CRO) that provides
bioanalytical and in vitro Absorption Distribution Metabolism Excretion
Toxicology (ADMET) services for the biotechnology and pharmaceutical industries,
has appointed Dr. Adrian Sheldon as associate director of In Vitro ADMET
Services. In this role, Dr. Sheldon will build [...]
Evotec Announces Research Agreement With Biogen Idec - HAMBURG, Germany and OXFORD, UK, Sept. 9, 2009 (GLOBE NEWSWIRE) -- Evotec AG
(Frankfurt:EVT) (Nasdaq:EVTC), a leading provider in the discovery and
development of novel small molecule drugs, today announced that it has entered
into a research agreement with Biogen Idec (Nasdaq:BIIB), a leading
biopharmaceutical company headquartered in Cambridge, Mass., USA.
Evotec will use its expertise and technologies in protein [...]
KINAXO launches KinAffinity® services for efficient profiling of kinase inhibitors in cells or tissue - Martinsried, Germany, October 01, 2009 / b3c newswire / - KINAXO Biotechnologies GmbH announced today that it added KinAffinity® to its service portfolio. KinAffinity® provides invaluable information about a kinase inhibitor’s selectivity in a cell or tissue of interest. It simultaneously determines affinities for native kinases expressed within a cellular [...]
Plexxikon Receives Key Patents on Novel Compounds for Multiple Programs - BERKELEY, Calif.–(BUSINESS WIRE)–Plexxikon Inc. today announced the issuance of key composition-of-matter patents covering novel compounds discovered through the company’s Scaffold-Based Drug Discovery™ platform. Plexxikon’s pipeline of preclinical and clinical stage product opportunities currently span [...]
Thermo Fisher Scientific Accelerates Drug Discovery Process With New Maybridge Quick2Lead™ Compound Kits - Thermo Fisher Scientific, the world leader in serving science, announced recently that it has introduced a novel tool to accelerate hit-to-lead programmes in the drug discovery process. Its Maybridge Quick2Lead™ Compound Kits are designed to save time and money by enabling rapid compound library synthesis around bioactive “hits” emerging from screening assays. The kits are [...]
Plexxikon Receives Key Patents on Novel Compounds for Multiple Programs - BERKELEY, Calif.–(BUSINESS WIRE)–Plexxikon Inc. today announced the issuance of key composition-of-matter patents covering novel compounds discovered through the company’s Scaffold-Based Drug Discovery™ platform. Plexxikon’s pipeline of preclinical and clinical stage product opportunities currently span [...]
European Molecular Biology Laboratory (EMBL) Signs Agreement to License Themis and Surflex-Dock Technologies from Tripos - ST. LOUIS, Mo.–(BUSINESS WIRE)–Tripos™, a leading provider of drug discovery informatics products and services, today announced an agreement with the European Molecular Biology Laboratory (EMBL), Europe’s leading research institution for molecular biology, to license [...]
ZINC Database - emolecule repository - What is ZINC? It is a free database of millions of commercially-available compounds for virtual screening in ready-to-dock format.
Why is it needed? Compounds that are available today can become unavailable in six months because of unavailability of the underlying reagents. For most vendors, the list of available compounds is significantly smaller than the list of [...]
IPR story 12- Patenting a mere idea
Virtual Screening Gives Drug Design a Boost - San Diego, CA (OBBeC) – Researchers at the University of California, San Diego, developed a unique computational approach to identify key compounds that could lead to new drugs to combat African sleeping sickness — a disease spread by the biting tsetse fly and caused by the parasite Trypanosoma brucei.
Around 150,000 people per year get African [...]
WuXi PharmaTech Inks New Three-year Deal with Pfizer - WuXi PharmaTech (NYSE: WX) has signed a new three-year CRO deal with Pfizer (NYSE: PFE) to collaborate on in vitro ADME (Absorption, Distribution, Metabolism and Excretion) services. Although WuXi has already been providing the services to Pfizer, WuXi said the new agreement “strengthens an already productive relationship.” WuXi also provides Pfizer with synthetic chemistry, parallel [...]
TimTec and Collaborative Drug Discovery Team Up to Provide Chemically Searchable Natural Products and Derivatives Available to the Scientific Community - TimTec LLC., the international distributor of synthetic organic and natural compounds, and Collaborative Drug Discovery, Inc. (CDD), the community based research information management enterprise, announced today that the CDD web-based software now hosts TimTec’s Natural Product Library and Natural Derivatives Library. The TimTec natural product and derivative compounds are now available as a structure searchable [...]
TOCRIS SIGNS EXCLUSIVE DEAL TO SUPPLY GEFITINIB - September 4th, 2008 - Tocris Bioscience announced today the signing of an exclusive deal with AstraZeneca to supply Gefitinib (also known as Iressa and ZD1839) to preclinical researchers working on the mechanisms underlying cancer development. For the first time, scientists will be able to buy authentic, fully licensed, non-formulated Gefitinib as an off-the shelf product [...]
Idealp-Pharma launches « hit-to-candidate » services - Services to accelerate programs from biological target to first-in-man use Idealp-Pharma is launching fully integrated drug discovery and preclinical development services combining medicinal chemistry, cheminformatics,
screening, early ADMET and preclinical development capabilities to speed up
partner’s and client’s small molecules programs from biological target to firstin-
man use.
According to Serge Petit, PhD, President and CEO, “Being a one-stop-shop [...]
4th Annual International Conference on Compound Libraries - in Dusseldorf, Germany from 6th to 8th October 2008. - From Focused Compound Libraries to optimised Hit-to-Lead - that’s the motto of IQPC’s 4th international conference on “Compound Libraries” (formerly “Focused Compound Libraries”). Nowadays the pharmaceutical industry is under enormous pressure, and the key for the industry to survive is faster and more efficient drug discovery. To improve their lead generation process and library, pharmaceutical [...]
Sponsored Links
|
|
